A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)
Public ClinicalTrials.gov record NCT02034916. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 2, 2-STAGE, 2-COHORT STUDY OF TALAZOPARIB (BMN 673) ADMINISTERED TO GERMLINE BRCA MUTATION SUBJECTS WITH LOCALLY ADVANCED AND/OR METASTATIC BREAST CANCER
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this 2-stage, 2-cohort Phase 2 trial is to evaluate the safety and efficacy of talazoparib (also known as BMN 673) in subjects with locally advanced or metastatic breast cancer with a deleterious germline BRCA 1 or BRCA 2 mutation. Subjects will be assigned to either Cohort 1 or 2 based on prior chemotherapy for metastatic disease: * Cohort 1) Subjects with a documented PR or CR to a prior platinum-containing regimen for metastatic disease with disease progression \> 8 weeks following the last dose of platinum; or * Cohort 2) Subjects who have received \> 2 prior chemotherapy regimens for metastatic disease and who have had no prior platinum therapy for metastatic disease
Study identification
- NCT ID
- NCT02034916
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 84 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 13, 2013 (Actual)
- Primary completion
- Sep 1, 2016 (Actual)
- Completion
- Oct 31, 2018 (Actual)
- Last update posted
- Oct 14, 2019
2013 – 2018
United States locations
- U.S. sites
- 37
- U.S. states
- 7
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Marin Cancer Care, Inc. | Greenbrae | California | 94904 | — |
| UCLA West Medical Pharmacy Attn: Steven L. Wong, PharmD | Los Angeles | California | 90095-1772 | — |
| UCLA West Medical Pharmacy, Attn: Steven L. Wong, Pharm.D. | Los Angeles | California | 90095-7349 | — |
| TRIO-US Central Administration | Los Angeles | California | 90095 | — |
| Stanford Women's Cancer Center | Palo Alto | California | 94304 | — |
| UCLA Hematology Oncology- Porter Ranch | Porter Ranch | California | 91326 | — |
| Torrance Health Association, DBA Torrance Memorial Physician Network/Cancer Care Associates | Redondo Beach | California | 90277 | — |
| University of California, San Francisco: Helen Diller Comprehensive Cancer Center | San Francisco | California | 94115 | — |
| UCLA Hematology-Oncology | Santa Monica | California | 90404 | — |
| Stanford Cancer Institute | Stanford | California | 94305 | — |
| Stanford Hospital and Clinics | Stanford | California | 94305 | — |
| Sylvester at Deerfield Beach | Deerfield Beach | Florida | 33442 | — |
| Memorial Cancer Institute at Memorial Regional Hospital | Hollywood | Florida | 33021 | — |
| Memorial Regional Hospital | Hollywood | Florida | 33021 | — |
| University of Miami Hospital & Clinics | Miami | Florida | 33136 | — |
| Memorial Breast Cancer Center at Memorial Hospital West | Pembroke Pines | Florida | 33028 | — |
| Memorial Cancer Institute at Memorial Hospital West | Pembroke Pines | Florida | 33028 | — |
| Memorial Hospital West | Pembroke Pines | Florida | 33028 | — |
| Sylvester at Plantation | Plantation | Florida | 33324 | — |
| ICRC | Indianapolis | Indiana | 46202-5116 | — |
| Indiana University Health Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| Investigational Drug Services | Indianapolis | Indiana | 46202 | — |
| IU Health University Hospital | Indianapolis | Indiana | 46202 | — |
| Sidney & Lois Eskenazi Hospital | Indianapolis | Indiana | 46202 | — |
| Springmill Medical Clinic | Indianapolis | Indiana | 46290 | — |
| Anne Arundel Medical Center (AAMC), Annapolis Oncology and Hematology | Annapolis | Maryland | 21401 | — |
| Anne Arundel Medical Center (AAMC), Research Pharmacy | Annapolis | Maryland | 21401 | — |
| Anne Arundel Medical Center (AAMC) | Annapolis | Maryland | 21401 | — |
| Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins | Baltimore | Maryland | 21231 | — |
| Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins, Green Spring Station | Lutherville | Maryland | 21093 | — |
| Memorial Sloan Kettering Evelyn H. Lauder Breast Center | New York | New York | 10065 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | — |
| Memorial Sloan Kettering Rockville Centre | Rockville Centre | New York | 11570 | — |
| University of Tennessee Medical Center | Knoxville | Tennessee | 37920 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
| The Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030-4009 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02034916, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 14, 2019 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02034916 live on ClinicalTrials.gov.